US multi-state cannabis operator running dispensaries and cultivation facilities, with a leading position in Florida.
US multi-state cannabis operator running dispensaries and cultivation facilities, with a leading position in Florida.
Grows, makes and sells its own products through its own dispensaries, because Florida's licence rules require that vertical integration. Cannabis is still illegal under US federal law, so tax rule 280E bars most normal business deductions, raising its tax bill. It acquired Harvest Health in 2021 to reach more states.
Moat: narrow (regulatory licence, scale, brand). State cannabis licenses are limited and hard to obtain, especially its dominant Florida position.
Headquarters: Tallahassee, Florida, US · Founded: 2014 · Employees: 5,000
Size Trulieve Cannabis (TRLV) is a United States Consumer Staples company (Agricultural Commodities/Milling) with a market value of $1.93B, the 1797th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.02 on 18 Nov 2026.
Performance Over six months the shares gained 25.4%, against -13.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue fell 9.1% over the last twelve months (peer median +4.3%); the operating margin is 15.1% (peer median 5.9%).
Valuation It trades at 28.5× forward earnings against a peer median of 17.2× (3rd most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 11% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.0 points above its cost of capital (12.5% WACC).
Short interest Short interest is 2.3% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.08B | $1.18B | $1.19B | $1.13B | $1.22B |
| Revenue growth | — | 0% | +5% | -7% | — |
| Gross profit | $553M | $594M | $603M | $479M | $573M |
| EBITDA | $320M | $332M | $270M | $259M | $289M |
| Net income | -$446M | -$116M | -$155M | -$527M | -$246M |
| Free cash flow | $172M | $229M | $149M | $161M | -$155M |
| Capital expenditure | $65.7M | $60.5M | $148M | $55.6M | $189M |
| Total debt | $582M | $564M | $824M | $429M | $433M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Trulieve Cannabis TRLV | $1.93B | +25% | -9% | 15% | 28.5× | 11.2% |
| Curaleaf CURA.TO | $2.10B | -17% | +5% | 1% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TRLV | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.1% | -4.0% | 6th lowest of 21 |
| 6-month return | +25.4% | -13.1% | 3rd highest of 20 |
| Distance from 52-week high | -24.6% | -32.0% | 9th highest of 21 |
| Revenue growth (TTM) | -9.1% | +4.3% | 2nd lowest of 21 |
| Operating margin | 15.1% | 5.9% | 6th highest of 21 |
| Forward P/E | 28.5× | 17.2× | 3rd most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 11.2% | 1.9% | 5th most demanding of 13 |
| Growth delivered (Del g) | +17.8% | +12.0% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -6.6 pp | -3.4 pp | 5th least demanding of 13 |
| ROIC minus cost of capital | +0.0 pp | -2.1 pp | 9th highest of 21 |
| EV / EBITDA | 6.8× | 11.5× | 2nd cheapest of 9 |
| Net debt / EBITDA | 0.8× | 1.8× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Trulieve Cannabis TRLV | United States | $1.93B | +25% | -9% | 15% | 28.5× | 11.2% | +17.8% |
| Guangxi Yuegui Guangye 000833.SZ | China | $1.96B | -46% | +67% | 30% | 8.6× | 0.4% | -0.9% |
| BioMar Group A/S BIOMAR.CO | Denmark | $1.85B | -31% | 0% | 6% | 13.6× | -1.2% | -0.5% |
| Genus GNS.L | United Kingdom | $1.81B | -13% | -2% | 13% | 21.2× | 16.1% | +2.8% |
| Beijing Dbn Technology 002385.SZ | China | $1.78B | -22% | -1% | -6% | n/a | n/a | n/a |
| Curaleaf CURA.TO | Canada | $2.10B | -17% | +5% | 1% | n/a | n/a | n/a |
| Uie UIE.CO | Denmark | $1.71B | +8% | +11% | 40% | n/a | -15.2% | +13.1% |
| Lien Hwa Industrial 1229.TW | Taiwan | $2.20B | +2% | +1% | 19% | n/a | 12.0% | +7.3% |
| Tecon Biology 002100.SZ | China | $1.69B | +14% | -8% | -5% | n/a | n/a | n/a |
| Yuan Longping High-Tech Agriculture 000998.SZ | China | $1.65B | -14% | -5% | 5% | 43.5× | n/a | n/a |
| B.F BFG.MI | Italy | $2.26B | +59% | +30% | -2% | 85.0× | n/a | n/a |
| Jiangsu Provincial Agricultural Reclamation & Dev 601952.SS | China | $1.63B | -13% | -5% | 4% | 19.0× | -2.9% | +3.2% |
| Fuji Oil 2607.T | Japan | $2.30B | +24% | +4% | 5% | 14.4× | 0.4% | +16.2% |
| Bumitama Agri P8Z.SI | Singapore | $1.61B | -28% | +9% | 25% | 8.9× | -16.8% | +12.9% |
| AWL Agri Business AWL.NS | India | $2.38B | -15% | +18% | 2% | 18.0× | 13.9% | +15.0% |
| LT Foods LTFOODS.NS | India | $1.56B | +2% | +24% | 8% | 12.8× | 25.8% | +18.2% |
| Shenzhen Agricultural Products 000061.SZ | China | $1.52B | -22% | -22% | 12% | 24.4× | 3.5% | +15.6% |
| China Modern Dairy 1117.HK | Hong Kong | $1.50B | +29% | +5% | -15% | 13.7× | n/a | n/a |
| Liuliumei 6658.HK | Hong Kong | $1.46B | n/a | +6% | 12% | n/a | n/a | n/a |
| Yunnan Shennong Agricultural Industry 605296.SS | China | $2.57B | +10% | +2% | -19% | n/a | n/a | n/a |
| Shandong Yisheng Livestock & Poultry Breeding 002458.SZ | China | $1.44B | -25% | +15% | 17% | 17.2× | 5.4% | +11.1% |